|
Originally published In Press as doi:10.1074/jbc.M206172200 on December 23, 2002
J. Biol. Chem., Vol. 278, Issue 9, 7699-7708, February 28, 2003
Isolation and Characterization of Androgen Receptor
Mutant, AR(M749L), with Hypersensitivity to 17- Estradiol
Treatment*
Tin Htwe
Thin,
Liang
Wang,
Eungseok
Kim,
Loretta L.
Collins,
Ravi
Basavappa, and
Chawnshang
Chang
From the George Whipple Laboratory for Cancer Research Departments
of Pathology, Urology, and Radiation Oncology, and the Cancer Center,
University of Rochester, Rochester, New York 14642
Estrogens, primarily 17 -estradiol
(E2), may play important roles in male
physiology via the androgen receptor (AR). It has already been shown
that E2 modulates AR function in LNCaP prostate cancer cells and xenograft CWR22 prostate cancer tissues. Using a
molecular model of E2 bound-AR-ligand binding domain (LBD)
and employing site-directed mutagenesis strategies, we screened several AR mutants that were mutated at E2-AR contact sites. We
found a mutation at amino acid 749, AR(M749L), which confers AR
hypersensitivity to E2. The reporter assays demonstrate
that E2 can function, like androgen, to induce AR(M749L)
transactivation. This E2-induced AR mutant transactivation
is a direct effect of the AR(M749L), because the transactivation was
blocked by antiandrogens. The hypersensitivity of AR(M749L) to
E2 is not due to increased affinity of AR(M749L) for
E2, rather it may be due to the existence of the proper
conformation necessary to maintain E2 binding to the AR-LBD
long enough to result in E2-induced transactivation.
AR(M749L) transactivation can be further enhanced in the presence of AR coregulators, such as ARA70 and SRC-1. Therefore, amino acid 749 may
represent an important site within the AR-LBD that is involved in
interaction with E2 that, when mutated, allows
E2 induction of AR transactivation.
*
This work was supported by a George Whipple Professorship
Endowment and National Institutes of Health Grant DK60905.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pathology,
George Whipple Laboratory for Cancer Research, 601 Elmwood Ave., Box
626, University of Rochester, Rochester, NY 14642. Tel.: 585-273-4500;
Fax: 585-756-4133; E-mail: chang@URMC.rochester.edu.
Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Wang, C.-L. Hsu, J. Ni, P.-H. Wang, S. Yeh, P. Keng, and C. Chang
Human Checkpoint Protein hRad9 Functions as a Negative Coregulator To Repress Androgen Receptor Transactivation in Prostate Cancer Cells
Mol. Cell. Biol.,
March 1, 2004;
24(5):
2202 - 2213.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|